

Magle Group is pleased to announce Magle PharmaCept's participation in the DPC, German Pancreatic Club congress, set to take place February 27-March 1, 2025, in Heidelberg, Germany.

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) is pleased to announce Magle PharmaCept's participation in the DPC, German Pancreatic Club congress, set to take place February 27-March 1, 2025, in Heidelberg, Germany. The event is the 44th annual meeting and will cover multidisciplinary aspects of malignant and inflammatory pathologies of the pancreas.

The event, recognized as a major congress joining key experts and researchers in the field of modern pancreatic surgery. The DPC unites clinical and basic researchers in the field of the pancreas and its pathology. The main topics are pancreatic cancer, acute and chronic pancreatitis and pancreatic cystic lesions as well as pancreatic surgery.

Magle PharmaCept will host a symposium March 1, featuring three prominent clinical experts in the field of modern pancreatic surgery in which experts will report on the clinical benefits and latest clinical evidence of SmartPAN®.

Magle PharmaCept will also during the congress showcase SmartPAN as a first in class pancreatic fluid leakage indicator.

SmartPAN is a CE-marked medical device for indication of pancreatic fluid leakage. The product is based on Magle Group's proprietary polymer technology, DSM® (Degradable Starch Microsphere).

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

Magle Group is pleased to announce Magle PharmaCept's participation in the DPC, German Pancreatic Club congress, set to take place February 27-March 1, 2025, in Heidelberg, Germany.